Johnson & Johnson (NYSE:JNJ) today reported fourth-quarter earnings that beat the consensus forecast on Wall Street, but its sales numbers were slightly off amid declining medical device revenue.
The New Brunswick, N.J.–based pharmaceutical, medical device and consumer products giant reported profits of $4.0 billion, or $1.50 per share, on sales of $20.7 billion for the three months ended Dec. 30, 2019, for a bottom-line gain of 31.8% and sales growth of 1.7% compared with Q4 2018.
Adjusted to exclude one-time items, earnings per share were $1.88, a penny ahead of The Street, where analysts were looking EPS of $1.87 on sales of $20.8 billion.
Pharmaceutical sales were up 3.6% to $42.2 billion in 2019.
Tell Us What You Think!